We are a national coalition of AIDS activists, many living with HIV/AIDS,working together to end the AIDS epidemic by advancing research on HIV/AIDS

Drug Development Committee

ATAC's Drug Development Committee (DDC) works with government, academia and the pharmaceutical industry to provide a community perspective into the development of new HIV drugs and the utilization of HIV therapies.

Co-Chairs:

David Evans
devans@atac-usa.org

Jeff Berry
jeffberry@atac-usa.org

*****

DDC Representative to the Board of Directors

Michael Dorosh

Join the DDC! To become a DDC member, you must apply to ATAC and be accepted as an ATAC member. Click here to get the process started. Please note: to apply for DDC membership, you will be asked to answer questions related to financial disclosure of any income received from the Pharmaceutical Industry (if any).

If you have any questions, or have problems accessing the online membership application, please contact us:

ATAC
440 Park Avenue South, 2nd Floor
New York, NY 10016

Phone: 617.267.0998 Email: coalitionmanager@atac-usa.org.

• Abbott Laboratories
• Boehringer Ingelheim 
• Bristol-Myers Squibb
• Chiron Corporation
• EMD Serono
• Gilead Sciences 
• GlaxoSmithKline 
• Koronis Pharmaceuticals
• Pfizer
• Merck & Co.
• Roche 
• Schering-Plough
• Theratechnologies
• Tibotec
• Trimeris

Information Resources:

AIDS/HIV Glossary of Terms from the U.S. National Institutes of Health

AIDSinfo Drugs Database fact sheets on HIV-related drugs

Clinical Trials for HIV/AIDS Drugs from ClinicalTrials.gov